$7.870
-0.069 (-0.88%)At close
- High
- 7.920
- Open
- 7.910
- VWAP
- 7.84
- Vol
- 554.83K
- Mkt Cap
- —
- Low
- 7.745
- Amount
- 4.35M
- EV/EBITDA, TTM
- 32.82
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Analyst Ratings (2)
HC Wainwright & Co.
$11
2025-04-08
HC Wainwright & Co.
2025-04-08
Price Target
$11
HC Wainwright & Co.
$11
2025-03-31
HC Wainwright & Co.
2025-03-31
Price Target
$11
HC Wainwright & Co.
$11
2025-03-17
HC Wainwright & Co.
2025-03-17
Price Target
$11
HC Wainwright & Co.
$11
2025-03-10
HC Wainwright & Co.
2025-03-10
Price Target
$11
Ladenburg Thalmann
$8.1
2025-03-05
Ladenburg Thalmann
2025-03-05
Price Target
$8.1
Valuation Metrics
Events Timeline
News
4.003-17BenzingaHC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $11 Price Target
4.503-13BusinesswireChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
4.503-13NewsfilterChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
- 1.003-11Newsfilter
ChromaDex to Present at the 37th Annual Roth Conference
- 4.003-05Benzinga
Ladenburg Thalmann Maintains Buy on ChromaDex, Raises Price Target to $8.1
CDXC FAQ — answered by Alphio AI
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).
2 analysts cover CDXC: 2 rate it Buy, 0 Hold and 0 Sell.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.